A Cutting-edge Therapy For Non-Hodgkin's Lymphoma

SEnuke: Ready for action

Non-Hodgkin's lymphoma is a slow-growing, lethal cancer of the defense mechanisms that develops when white blood cells increase uncontrollably in the lymph nodes. Get further on this related link - Click here: An Oasis Of Healing Patient Gives Testimonial On Surviving Hodgkin's Lymphoma. Every year in the U.S. This thought-provoking An Oasis Of Healing Patient Gives Testimonial On Surviving Hodgkin's Lymphoma essay has some unique lessons for the reason for this viewpoint. alone, 55,000 new cases are identified. Fortunately, story, extremely personalized treatments are increasingly being developed. Using a current medical discovery, patients are now able to receive individualized treatment that eliminates malignant cells while sparing regular, healthy cells.

Conventional treatments usually consist of chemotherapy and monoclonal antibody medications, which, along with targeting malignant B-cells, destroy healthier white blood cells that include a significant element of the immune system.

Biovest International is among a few companies working on patient-specific cancer vaccines. To learn additional info, please check-out: An Oasis Of Healing Patient Gives Testimonial On Surviving Hodgkin's Lymphoma. Biovest's personalized healing, BiovaxID, is currently being examined as cure for indolent (slow-growing) follicular B-cell non-Hodgkin's lymphoma, which affects 12,500 new people in the U.S. Click here An Oasis Of Healing Patient Gives Testimonial On Surviving Hodgkin's Lymphoma to explore the reason for it. Every year. The vaccine may ultimately be used to treat other cancers.

Personalizing BiovaxID starts with a sample of cancerous cells from the patient's lymph nodes. On the surface of the cells are special proteins, or antigens, detectable from the immune system. The physician directs this test of-the patient's cancer cells to Biovest's laboratory in Worcester, Mass. Here, experts combine the cells with another line of cells licensed from Stanford University. The cells blend, delivering the antigen proteins.

As the patient undergoes chemotherapy to kill most of the cancer cells, Biovest collects and purifies the patient's antigen proteins, which, after chemical modification, form the ingredient of the custom vaccine. The individualized vaccine is then delivered back to the physician, who inserts it in to the patient five times over six-months.

'Typical solutions for non-Hodgkin's don't exclusively target the tumor,' describes Dr. Carl M. Cohen, Biovest Chief Operating Officer. 'Our vaccine trains the patient's immunity system to target a specific protein on the tumor cells-one observed only on the tumor cells. BiovaxID just kills cancer cells. If you were to think of chemotherapy as a blunt instrument, our treatment is like tweezers.'

A 95 percent survival rate is shown by results from a Biovest study of 20 patients, begun at the National Cancer Institute a decade ago,. Forty-five % are still in remission. Based on historical information, just about half the people could have survived with conventional treatments. None would be in remission. (The patients remained disease-free for a average of eight years.)

Currently, Biovest is enrolling patients for a study to-be used at several key U.S. and European medical institutions. The test will include 460 people. Business officials hope to receive FDA approval for the vaccine by 2008..